Taipei, Taiwan Related Funds
| Fund Name | Location |
| Axon Ventures | California, San Diego, United States |
| BAIC Group | Beijing, Beijing, China |
| Bio/Med Investor Network | Atlanta, Georgia, United States |
| BuzzFeed | New York, New York, United States |
| Campus Founders Fund | Salt Lake City, United States, Utah |
| Conviction Investment Partners | Newcastle upon Tyne, North East, United Kingdom |
| DOT Capital | New York, New York, United States |
| DoubleRock | California, Menlo Park, United States |
| Health Care Service Corporation | Chicago, Illinois, United States |
| Hillingdon Ventures | - |
| Inventures Group | California, Palo Alto, United States |
| Jianmin Pharmaceuticals | - |
| Jollychic | China, Hangzhou, Zhejiang |
| Mingyuan Hongqiao Investment Management | China, Fujian, Xiamen |
| Success Group | China, Foshan, Guangdong |
| Tenex Greenhouse Ventures | Burlingame, California, United States |
| Ventura Family Office | Buenaventura, Colombia, Valle del Cauca |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Insilico Medicine | $255M | 22 Jun 2021 | Hong Kong Island, Hong Kong, China | ||
Origene Technologies | $16M | 24 Mar 2010 | Maryland, United States |
– Insilico Medicine announced that it has closed a $255m Series C.
– The financing led by Warburg Pincus, and participated by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, and new investors including CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners.
– The financing will be used to progress Insilico Medicine’s current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Insilico Medicine | $255M | 22 Jun 2021 | Hong Kong Island, Hong Kong, China | ||
Origene Technologies | $16M | 24 Mar 2010 | Maryland, United States |
